The study had a relatively low rate of adherence and retention, which is not uncommon in studies of symptomatic conditions. However, a higher incidence of pulmonary embolism, acute kidney injury, and atrial fibrillation was noted in the testosterone group. Of note, a higher incidence of pulmonary embolism, acute kidney injury, and atrial fibrillation was noted in the testosterone group. The primary endpoint occurred in 7% of the testosterone group and in 7.3% of the placebo group. Then, it will be discussed the association of T with the main risks for CVD, namely metabolic syndrome, type 2 diabetes mellitus, obesity, atherosclerosis, dyslipidaemia and hypertension. Cardiovascular diseases (CVD) are one of the leading causes of death worldwide.
Moreover, testosterone deficiency can cause a reduction in oxygen-carrying capacity, which can further compromise vascular health. Low testosterone levels result in a decrease in the production of nitric oxide, resulting in impaired vasodilation. When men age, their testosterone levels decline, which can lead to a process of hypogonadism and testosterone deficiency. Furthermore, testosterone can aid in red blood cell production, which is responsible for the transportation of oxygen throughout the body. Conversely, it can expand the number of blood platelet cells, allowing blood clot more easily and increase the risk of stroke. With this, it may be prudent to avoid usage of testosterone replacement in men with prior thromboembolic events, and perhaps even with those with paroxysmal atrial fibrillation or prior renal insufficiency.
Data from isolated vessels and animal models suggest that pharmacological doses of testosterone, or its potent intracellular metabolite dihydrotestosterone, produce vasodilation. Articles from Methodist DeBakey Cardiovascular Journal are provided here courtesy of Methodist DeBakey Heart & Vascular Center In a comprehensive overview of systematic reviews to date, Onasanya and colleagues from the Johns Hopkins School of Public Heath concluded that currently available data regarding an association between TRT and CV events are conflicted.40 At this time, a detailed discussion with patients about the risks and benefits of TRT is essential until further data is available. Similar to the previous reports, TRT resulted in a significant increase in hemoglobin levels.36 They concluded that TRT for hypogonadism does not appear to increase PSA or the risk of prostate cancer. In this study, fat biopsies were also used to show that the expression of insulin-signaling genes (IR-ß, IRS-1, AKT-2, and GLUT 4) was lower in men with TD and diabetes.
Coronary heart disease is a leading cause of premature death in men. Isolated hearts were subjected to 25 minutes of myocardial ischemia followed by 40 minutes of reperfusion. The hearts were isolated, then subjected to 25 minutes of ischemia followed by 40 minutes of reperfusion. Testosterone infusions, 5 minutes prior to myocardial ischemia, were given at a concentration of 10 ng/mL, approximately physiological levels.
Although VOCC function may differ in cultured cell lines, the results in primary cultured and freshly dissociated rat aortic myocytes (41) are consistent with the findings of these reports. This possibility is supported by previous in vivo studies that demonstrated that Tes-induced vasodilation of both canine coronary and porcine systemic arteries was nitric oxide (NO) dependent (3, 39). Clearly, these data suggest the presence of an endothelium-dependent mechanism at physiological concentrations of Tes (11–36 nmol/l). In this latter study, sensitivity to Tes-induced vasodilation was much higher in endothelium-intact than in endothelium-denuded vessels (1 nM vs. 30 μM; Ref. 55). Moreover, in electrophysiological (patch clamp) experiments measuring ion currents in single VSM cells, Tes acts at nanomolar concentrations (8, 17, 41, 58, 59) and even at circulating (36 nmol/l) concentrations (17, 58, 59) to inhibit Ca2+ channels.
The mean body mass index (BMI) for hypogonadal men was found to be 31.5 compared to 28.5 for eugonadal men. The evidence regarding the association between baseline T levels and lipid subfractions is conflicting; therefore, there is no clear consensus among the numerous authors who have investigated this association. Additional research is needed to further evaluate the association between low T levels and CAD severity. The prevalence of symptomatic TD ranges from 2.1% to 12.8% in middle-aged to older men, with an incidence of 12 new cases/1000 person-years in the United States and Europe. Testosterone deficiency (TD) is a well-established major medical condition that negatively impacts male sexuality, general health, and quality of life.
T levels were then measured in stored blood samples from initial study visits and analyzed for differences between the two groups. However, while these types of analyses attempt to control for covariates, they do not allow clear discernment as to whether T levels are directly related to CVD risk or, alternatively, serve as a marker of ill health overall. Multiple cross-sectional studies have examined the association between endogenous T levels and the presence of coronary artery disease. Observational studies performed to investigate the association between circulating T concentrations and CVD risk have yielded inconsistent findings. Nonetheless, controversy remains regarding treatment of male hypogonadism, in part due to a lack of clear understanding of the risk/benefit profile of therapy. Indeed, the recent development of selective AR modulators (SARMs) may permit the selective treatment of CVD and the avoidance of androgenic side effects (7, 72) in fulfillment of the proposed clinical applications of androgen therapy. Thus androgen replacement therapy with vasoselective androgens such as 5β-DHT, which exert little or no action on the AR receptor, may be an emerging therapeutic option for aging men to prevent vascular dysfunction such as HT, erectile dysfunction, and prostatic ischemia.

Gender: Female

Social links